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and New Haven, ConnecticutObjectives This study sought to investigate whether the everolimus-eluting stent (EES) is superior to
the paclitaxel-eluting stent (PES) with respect to long-term individual clinical outcomes.
Background Individual studies have indicated a clinical advantage of coronary EES compared with
PES with respect to restenosis and the composite endpoint of major adverse cardiac events. However,
these trials were not powered for superiority in low-frequency event rates and have reported limited
data beyond 1-year follow-up.
Methods We conducted a meta-analysis of the ﬁnal 3-year results from the international SPIRIT
(Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of
Patients With De Novo Native Coronary Artery Lesions) II, III, and IV clinical trials. Individual patient data
from 4,989 patients who were prospectively randomized to treatment with EES (n ¼ 3,350) or PES
(n ¼ 1,639) were pooled for analysis.
Results At 3-year follow-up, EES was superior to PES in reducing the following event rates: target
lesion failure (8.9% vs. 12.5%, hazard ratio [HR]: 0.71, 95% conﬁdence interval [CI]: 0.59 to 0.85;
p ¼ 0.0002), all-cause mortality (3.2% vs 5.1%, HR: 0.65, 95% CI: 0.49 to 0.86; p ¼ 0.003), myocardial
infarction (3.2% vs. 5.1%, HR: 0.64, 95% CI: 0.48 to 0.85; p ¼ 0.002), cardiac death or myocardial
infarction (4.4% vs. 6.3%, HR: 0.70, 95% CI: 0.54 to 0.90; p ¼ 0.005), ischemia-driven target lesion
revascularization (6.0% vs. 8.2%, HR: 0.72, 95% CI: 0.58 to 0.90; p ¼ 0.004), stent thrombosis (0.7% vs.
1.7%, HR: 0.45, 95% CI: 0.26 to 0.78; p ¼ 0.003), and major adverse cardiac events (9.4% vs. 13.0%,
HR: 0.71, 95% CI: 0.60 to 0.85; p ¼ 0.0002). No interaction was present between stent type and the
3-year relative rates of target lesion failure across a broad range of subgroups, with the exception
of diabetes and vessel (left anterior descending vs. other).
Conclusions In this large dataset with 3-year follow-up, coronary implantation of EES compared with
PES resulted in reduced rates of all-cause mortality, myocardial infarction, ischemia-driven target lesion
revascularization, stent thrombosis, and target lesion failure. Further research is warranted to
characterize possible interactions between stent type, diabetes, and vessel. (J Am Coll Cardiol Intv
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915In several individual clinical trials, everolimus-eluting stents
(EES) were shown to have advantages over paclitaxel-
eluting stents (PES), including reduced rates of restenosis,
target lesion revascularization (TLR), and composite end-
points such as major adverse cardiac events (MACE) (1–8).
In addition, recent meta-analyses indicated that EES have
lower rates of stent thrombosis than other types of drug-
eluting and bare-metal stents do (9–11). However, few of
these studies have reported follow-up beyond 1 year, and
no study has been individually powered to investigate
differences in low-frequency event rates such as death or
myocardial infarction (MI).
We therefore conducted the present meta-analysis from
the prospective, multicenter, SPIRIT (Clinical Evaluation of
the Xience V Everolimus Eluting Coronary Stent System in
the Treatment of Patients With De Novo Native Coronary
Artery Lesions) clinical trials program (SPIRIT II, III, and
IV) that included randomization of 4,989 patients to EES
versus PES, with follow-up over 3 years.Abbreviations
and Acronyms
EES = everolimus-eluting
stent(s)
LAD = left anterior
descending
MACE = major adverse
cardiac events
MI = myocardial infarction
PCI = percutaneous coronary
intervention
PES = paclitaxel-eluting
stent(s)
TLF = target lesion failure
TLR = target lesionMethods
The SPIRIT II, III, and IV trial designs and primary results
have been previously described (1–8,12). In summary, all 3
trials were randomized, single-blind, active-control designs
comparing EES (an 81-mm strut thickness cobalt chromium
metallic stent that elutes everolimus from a durable ﬂuo-
rocopolymer [Xience V, Abbott Vascular, Santa Clara,
California]) versus PES (a 132-mm strut thickness stainless
steel stent that elutes paclitaxel from a durable polymer
[Taxus Express, Boston Scientiﬁc, Natick, Massachusetts])
(6). Exclusion criteria for high-risk patients and lesions
were: acute or recent MI; left ventricular ejection fraction
<30%; lesions that were in a bypass graft conduit; occluded
vessels; bifurcations (minor bifurcations were included in
SPIRIT IV); ostial lesions (ostial right coronary artery
lesions were included in SPIRIT IV); and severely calciﬁed
or tortuous vessels. The studies were individually approved
by the institutional review board at each participating center,
and consecutive, eligible patients signed informed, written
consent. All 3 trials used the same data element deﬁnitions,
enabling pooling of individual patient data for the present
meta-analysis. Table 1 shows the key methodological char-
acteristics of these 3 trials.North Carolina; #Abbott Vascular, Santa Clara, California; **Division of Cardiology,
Harvard Clinical Research Institute, Boston, Massachusetts; yyDivision of Cardiology,
Yale University Medical Center, New Haven, Connecticut; and the zzDivision of
Cardiology, Columbia University Medical Center/New York-Presbyterian Hospital,
New York, New York. The SPIRIT II, III, and IV trials were sponsored and funded
by Abbott Vascular. Dr. Dangas has reported that his spouse has received honoraria
for serving on the advisory board of Abbott Vascular and Boston Scientiﬁc. Dr.
Kereiakes has received consulting fees from Abbott Vascular, Boston Scientiﬁc, and
REVA Medical. Dr. Hermiller has received consulting fees from Abbott Vascular andClinical follow-up was scheduled at 30, 180, 270, and 365
days and then yearly; complete 3-year follow-up is available
from all 3 trials and, therefore, data until this time point
were used in the present analysis. Although the operators
were by necessity unblinded during the stent procedure, the
patient and staff involved in follow-up assessments remained
blinded, with a standardized follow-up interview script used
to reduce bias. In addition, all angiograms were reviewed
by dedicated core laboratories that were blinded to the
treatment assignment and followed established analytical
methods (13).
Data management. Independent study monitors veriﬁed all
case report form data. Reportable clinical events were adju-
dicated by an independent committee blinded to treatment
allocation. The data safety and monitoring committee of each
trial had periodically reviewed blinded safety data, each time
recommending the study to continue without modiﬁcation.
Independent core angiographic laboratory analyses were
performed by technicians blinded
to treatment assignment as pre-
viously described (14).
Endpoints and deﬁnitions. The
composite endpoint of ischemia-
driven target lesion failure (TLF)
was deﬁned as the occurrence of
cardiac death, target-vessel MI,
or ischemia-driven TLR by either
percutaneous coronary intervention
(PCI) or bypass graft surgery (15).
MACE was deﬁned as the
composite of cardiac death, MI,
or ischemia-driven TLR. Target
vessel failure was deﬁned as
all-cause death, MI, or ischemia-
driven target vessel revasculariza-
tion. Stent thrombosis was prospectively protocol-deﬁned as
an acute coronary syndromewith angiographic thrombus within
or adjacent to a stent, or in the absence of angiography, any
unexplained death or acute MI in the target lesion distribution
within 30 days. Stent thrombosis was also adjudicated using
the Academic Research Consortium deﬁnite or probable
criteria (16).
Statistical methods. Categorical variables were compared
by the Fisher exact test. Continuous variables are presented
as mean  SD and were compared by the Student t test.
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Table 1. Characteristics of the Prospective, Randomized SPIRIT Trials (N ¼ 4,989)
SPIRIT II SPIRIT III SPIRIT IV
Number of ITT patients 300 1,002 3,687
Randomization EES:PES 3:1 2:1 2:1
Lesion length, mm 28 28 28
Reference diameter, mm 2.5 to 3.75 2.5 to 3.75 2.5 to 3.75
Maximum lesions/patient 2 2 3
Routine angiography follow-up Yes Yes No
Timing 6 and 24 months 8 months d
Completed, n (%) 275 (91.7) at 6 months 436 (43.5) d
Aspirin duration Indeﬁnite Indeﬁnite Indeﬁnite
Clopidogrel duration 6 months 6 months 12 months
Longest follow-up, ﬁnal 5 yrs 5 yrs 3 yrs
d ¼ data not available; EES ¼ everolimus-eluting stent; ITT ¼ intention-to-treat analysis; PES ¼ paclitaxel-eluting stent; SPIRIT ¼ Clinical Evaluation
of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions.
Table 2. Baseline Clinical and Angiographic Characteristics
EES PES p Value
Clinical data n¼3,350 patients n¼1,639 patients
Age, yrs 63.2  10.5 63.2  10.2 0.98
Male 68.4 67.9 0.72
Body mass index, kg/m2 30.5  6.0 30.7  6.0 0.27
Hypertension 76.5 75.2 0.32
Hypercholesterolemia 75.2 74.8 0.75
Diabetes mellitus 30.9 31.2 0.87
Insulin-treated 8.1 8.7 0.51
Current smoker 22.8 22.8 1.00
Prior MI 21.8 19.7 0.10
Unstable angina 25.8 28.3 0.07
Angiographic data n ¼ 3,350 patients n ¼ 1,639 patients
Single-vessel disease 62.7 62.8 0.95
Double-vessel disease 27.4 28.4 0.43
Triple-vessel disease 9.9 8.7 0.16
Lesion data n ¼ 4,174 lesions n ¼ 2,059 lesions
LAD 40.6 40.7 0.96
LCX 25.1 25.7 0.64
RCA 34.2 33.6 0.61
LMCA 0.0 0.0 0.55
Thrombotic target lesion 2.0 1.6 0.27
Moderate or severe calciﬁcation 26.4 25.5 0.47
ACC/AHA class C target lesion 19.3 17.4 0.06
Quantitative measurements n ¼ 4,174 lesions n ¼ 2,059 lesions
Lesion length, mm 14.7  6.4 14.5  6.5 0.41
Reference vessel diameter, mm 2.8  0.5 2.8  0.5 0.38
Baseline MLD, mm 0.8  0.4 0.8  0.4 0.47
Baseline percentage of diameter stenosis 71.1  13.0 70.9  13.1 0.58
Final MLD, mm 2.34  0.5 2.35  0.5 0.46
Final percentage of diameter stenosis 14.5  7.5 14.7  7.8 0.35
Values are mean  SD or %.
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery;
LMCA ¼ left main coronary artery; MI ¼ myocardial infarction; MLD ¼ minimal lumen diameter; RCA ¼ right coronary artery; other abbreviations as
in Table 1.
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Table 3. Clinical Outcomes at 3 Years
EES (n ¼ 3,350) PES (n ¼ 1,639) HR (95% CI) p Value
All-cause mortality 3.2 5.1 0.65 (0.49–0.86) 0.003
Cardiac mortality 1.3 1.9 0.70 (0.44–1.10) 0.12
MI 3.2 5.1 0.64 (0.48–0.85) 0.002
Q-wave 0.3 0.8 0.41 (0.18–0.91) 0.02
Non–Q-wave 2.9 4.3 0.66 (0.49–0.90) 0.009
MI of target vessel 2.8 4.3 0.65 (0.47–0.88) 0.006
All-cause death or MI 6.1 9.5 0.65 (0.53–0.80) <0.0001
Cardiac death or MI 4.4 6.3 0.70 (0.54–0.90) 0.005
ischemia-driven TLR 6.0 8.2 0.72 (0.58–0.90) 0.004
Ichemia-driven TVR 9.9 11.4 0.87 (0.73–1.05) 0.14
MACE 9.4 13.0 0.71 (0.60–0.85) 0.0002
TLF 8.9 12.5 0.71 (0.59–0.85) 0.0002
TVF 12.9 15.3 0.84 (0.71–0.98) 0.03
Stent thrombosis, protocol deﬁned 0.9 1.9 0.45 (0.27–0.75) 0.002
0–1 yrs 0.4 0.8 0.45 (0.20–0.98) 0.04
1–3 yrs 0.5 1.1 0.45 (0.23–0.89) 0.02
Stent thrombosis, ARC deﬁnite or probable 0.7 1.7 0.45 (0.26–0.78) 0.003
0–1 yrs 0.4 0.9 0.39 (0.19–0.82) 0.01
1–3 yrs 0.4 0.7 0.53 (0.22–1.24) 0.14
Values are 5. Rates are Kaplan-Meier estimates.
ARC¼ Academic Research Consortium; CI¼ conﬁdence interval; HR¼ hazard ratio; MACE¼major adverse cardiac events; TLF¼ target lesion failure;
TLR ¼ target lesion revascularization; TVF ¼ target vessel failure; TVR ¼ target vessel revascularization; other abbreviations as in Tables 1 and 2.
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Figure 1. Three-Year Differences in TLF
Comparison of the time-to-event curves for target lesion failure with follow-up
to 3 years in patients randomized to receive everolimus-eluting stents versus
paclitaxel-eluting coronary stents indicate superior rates with everolimus-
eluting stent. CI ¼ conﬁdence interval; DES ¼ drug-eluting stent; HR ¼ hazard
ratio; MI ¼ myocardial infarction; TLF ¼ target lesion failure; TLR ¼ target
lesion revascularization.
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917All data are presented in the intent-to-treat population,
consisting of all patients randomized, regardless of the
treatment actually received. Time-to-event curves using all
available follow-up data were also constructed using Kaplan-
Meier estimates and compared by log-rank test. Subgroup
analyses were conducted to further investigate the potential
impact of baseline variables on the TLF composite endpoint
using Cox proportional hazards regression with formal
interaction testing. Multivariable analyses were also con-
ducted using Cox regression to identify independent
predictors of 3-year clinical outcomes; candidate variables
included in each model are listed in the footnote of their
respective table. A 2-sided alpha ¼ 0.05 was used for all
superiority testing. All statistical analyses were performed
using SAS (version 9.1.3, SAS Institute, Cary, North
Carolina).
Results
A total of 4,989 patients were randomized to EES (3,350
patients with 4,174 treated lesions) versus PES (1,639
patients with 2,059 treated lesions); the patient contribution
from each individual trial is shown in Table 1. Baseline
clinical and angiographic characteristics were well matched
between the groups (Table 2). There were trends toward
fewer unstable angina patients and more American College
of Cardiology/American Heart Association Class C lesions
in the EES versus the PES group. Procedural outcomes ofPCI are also summarized in Table 2, and they did not differ
signiﬁcantly between the 2 groups.
Clinical outcomes. Three-year clinical event rates are
detailed in Table 3 and Figures 1 to 4. All point estimates
were consistently indicating an advantage of treatment with
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Figure 2. Three-Year Differences in Hard Clinical Endpoints
Comparisons of the time-to-event curves with follow-up to 3 years for all-cause mortality (A) and myocardial infarction (B) in patients randomized to receive ever-
olimus-eluting (E) stents versus paclitaxel-eluting (P) coronary stents indicated statistical signiﬁcant differences. Abbreviations as in Figure 1.
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Figure 3. Three-Year Differences in Cardiac Mortality and in the Composite Endpoint of Death or Nonfatal MI
Comparisons of the time-to-event curves for cardiac mortality and cardiac mortality or myocardial infarction in patients randomized to receive everolimus-eluting (E)
stents (A) versus paclitaxel-eluting (P) coronary stents (B) are depicted. Abbreviations as in Figure 1.
Dangas et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 6 , N O . 9 , 2 0 1 3
Everolimus- vs. Paclitaxel-Eluting Stents Meta-Analysis S E P T E M B E R 2 0 1 3 : 9 1 4 – 2 2
918
0.92
0.39
0.67
0.35
0 0.5 1 1.5 2 2.5
0.80
0.36
1.13
0.51
0 0.5 1 1.5 2 2.5
Everolimus DES
N=3350
Paclitaxel DES
N=1638
Stent thrombosis (%)
0.87%
1.93%
p=0.002
Early + Late 
(up to 1 year)
Very Late 
(>1 year)
Everolimus DES
N=3350
Paclitaxel DES
N=1638
Early + Late 
(up to 1 year)
Very Late 
(>1 year)
p=0.003
0.74%
1.65%
HR [95%CI] = 0.39
[0.19, 0.82], p=0.01
1 year HR
Stent thrombosis (%)
HR [95%CI] = 0.45 
[0.20, 0.98], p=0.04
1 year HR
A B
Figure 4. Three-Year Differences in Stent Thrombosis After Random Assignment
Bar graphs indicating differences in stent thrombosis rates with follow-up to 3 years after random assignment to treatment with everolimus-eluting stents versus
paclitaxel-eluting coronary stents. Results were adjudicated according to the originally speciﬁed protocol deﬁnition (A) and also in accordance with the Academic
Research Consortium deﬁnite or probable stent thrombosis deﬁnition (B). In addition to 3-year cumulative rates, their occurrences within 1-year of stent implantation
(early plus late stent thrombosis) and beyond this time point (very late stent thrombosis) are also depicted. Abbreviations as in Figure 1.
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919EES versus PES. EES resulted in statistically signiﬁcant
reductions in the individual 3-year endpoints of all-cause
mortality, MI (including the individual subcategories of
Q-wave, non–Q-wave, and target vessel MI), ischemia-
driven TLR, and stent thrombosis (both protocol- and
Academic Research Consortium–deﬁned). Stent thrombosis
was reduced with EES compared with PES both within the
ﬁrst year after stent implantation, and between years 1 and 3
(Fig. 4). Superiority of EES was also present for the
composite endpoints of death or MI, cardiac death or MI,
MACE, TLF, and target vessel failure. By multivariable
analysis, randomization to EES versus PES was an inde-
pendent predictor of all individual and composite endpoints
examined: all-cause mortality; MI; ischemia-driven TLR;
TLF; and stent thrombosis (Table 4).
Subgroup analyses according to various baseline or proce-
dure variables in relation to the TLF outcome at 3-year
follow-up are shown in Table 5. The point estimates were
consistently in favor of EES compared with PES, with no
signiﬁcant interactions detected except for subgroups
according to diabetic status and target lesion location. With
respect to the diabetic subgroup interaction, EES was
superior to PES in nondiabetic patients with respect to
TLF at 3 years, whereas diabetic patients had comparable
event rates with both stents (p for interaction ¼ 0.02). This
interaction was most pronounced among the insulin-treated
diabetic subgroup, whereas no signiﬁcant interaction was
observed when only the non-insulin-treated diabetic
subgroup was considered. A large margin of superiority for
EES versus PES in TLF at 3 years was also observed in the
subgroup undergoing PCI of the left anterior descending
(LAD) coronary artery, whereas both stents resulted incomparable results in non-LAD coronary arteries (p for
interaction ¼ 0.03).Discussion
Previous results of the SPIRIT II and III trials showed
superiority of EES versus PES in angiographic restenosis
(1,2), and noninferiority with respect to composite safety
and efﬁcacy endpoints at 1- and 2-year follow-up (3–8).
Clinical superiority of EES over PES for TLF and other
composite safety and efﬁcacy endpoints was ﬁrst docu-
mented in the SPIRIT IV trial at 1-year follow-up (3). The
present meta-analysis further substantiates and extends these
ﬁndings by demonstrating: 1) that the beneﬁts of EES
relative to PES were not only sustained but also continued to
increase in magnitude over 3-year follow-up; and 2) signif-
icant reductions with EES compared with PES are also
present for the safety endpoints of all-cause and cardiac
death, MI, and stent thrombosis, ﬁndings made possible by
the greater power of the combined dataset.
Differences in death andMI are rarely demonstrated in PCI
trials in which 2 devices are compared (17). Therefore, the
reduction in the individual endpoints of all-cause death and
MI present with EES compared with PES from the current
meta-analysis supports the contention that new-generation
devices can indeed affect pathobiological processes that may
afford improved outcomes in “hard endpoints” over time. We
have previously highlighted that: 1) stent restenosis and
thrombosis are distinct complications; 2) each one of them can
affect patient outcomes; and 3) there is a tradeoff between
these 2 events in patients treated with PES versus bare-metal
Table 4. Independent Predictors of 3-Year Events by Multivariable Analysis
HR (95% CI) p Value
Target lesion failure
2 lesions treated versus 1 1.54 (1.23–1.92) 0.0001
Treatment with EES versus PES 0.66 (0.54–0.81) <0.0001
2 stents implanted versus 1 1.50 (1.14–1.95) 0.003
Reference vessel diameter 0.67 (0.54–0.84) 0.0006
ACC/AHA class, A/B1 versus B2/C 0.73 (0.59–0.90) 0.003
Target vessel, LAD versus other 1.35 (1.10–1.65) 0.004
Prior myocardial infarction 1.37 (1.09–1.72) 0.007
Diabetes mellitus 1.32 (1.07–1.64) 0.01
Presence of thrombus 0.33 (0.12–0.90) 0.03
Post-dilation balloon use 0.80 (0.65–0.98) 0.03
All-cause mortality
Age, yrs 1.07 (1.05–1.09) <0.0001
Current smoking 2.35 (1.63–3.39) <0.0001
Treatment with EES versus PES 0.63 (0.47–0.86) 0.003
Diabetes mellitus 1.45 (1.05–2.00) 0.02
Minimal lumen diameter, mm 1.50 (1.03–2.18) 0.04
Myocardial infarction
Lesion length, per 10 mm 1.39 (1.14–1.71) 0.002
Current smoking 1.61 (1.16–2.25) 0.005
Treatment with EES versus PES 0.60 (0.44–0.82) 0.001
Diabetes mellitus 1.61 (1.17–2.23) 0.004
Prior myocardial infarction 1.61 (1.15–2.26) 0.006
Post-dilation balloon use 0.70 (0.51–0.96) 0.03
GP IIb/IIIa inhibitor use 1.44 (1.01–2.05) 0.04
Ischemia-driven target lesion revascularization
Reference vessel diameter, mm 0.51 (0.39–0.67) <0.0001
2 lesions treated versus 1 1.51 (1.17–1.94) 0.001
Age, yrs 0.98 (0.97–0.99) 0.0003
2 stents implanted versus 1 1.65 (1.23–2.20) 0.0008
Treatment with EES versus PES 0.69 (0.55–0.87) 0.002
Target vessel ¼ LAD versus others 1.35 (1.07–1.71) 0.01
Stent thrombosis, ARC deﬁnite or probable
Current smoking 3.25 (1.81–5.84) <0.0001
Bailout stent usage 4.81 (2.31–10.01) <0.0001
Treatment with EES (versus PES) 0.39 (0.22–0.69) 0.001
Prior myocardial infarction 2.58 (1.43–4.68) 0.002
Diabetes mellitus 2.33 (1.29–4.21) 0.005
Bifurcation lesion 2.25 (1.26–4.01) 0.006
Post-dilation balloon use 0.49 (0.26–0.92) 0.03
Current smoking 3.25 (1.81–5.84) <0.0001
Candidate variables included in the models were: 1) target lesion failure model: severe angina class III or IV, diabetes mellitus, hypertension, target
vessel ¼ LAD, target lesion length, previous myocardial infarction, post-procedure dissection, ACC/AHA lesion class, treatment with EES versus PES,
sex, number of stents implanted, number of treated lesions, post-dilation balloon use, reference vessel diameter; 2) all-cause mortality model: age,
diabetes mellitus, hypertension, target vessel ¼ LAD, MLD, ACC/AHA lesion class, treatment, reference vessel diameter, current tobacco use, presence
of thrombus; 3) myocardial infarction model: prior cardiac interventions, diabetes mellitus, hypertension, GP IIb/IIIa inhibitor use, target lesion length,
prior myocardial infarction, number of diseased vessels, post-procedure dissection, ACC/AHA lesion class, treatment with EES versus PES, number of
stents implanted, post-dilation balloon use, current smoking status; 4) target lesion revascularization model: age, diabetes mellitus, target vessel ¼
LAD, target lesion length, post-procedure dissection, ACC/AHA lesion class, treatment with EES versus PES, number of stents implanted, number of
treated lesions, reference vessel diameter; 5) stent thrombosis model: age, bifurcation, bailout stent usage, maximum balloon pressure over the
entire procedure, severe angina class III or IV, prior cardiac interventions, diabetes mellitus, target vessel ¼ LAD, target lesion length, prior myocardial
infarction, in-segment MLD, treatment with EES versus PES, number of treated lesions, post-dilation balloon use, current smoking status.
GP ¼ glycoprotein; other abbreviations as in Tables 1 to 3.
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Table 5. Subgroup Analyses for Target Lesion Failure at 3-Year Follow-up
Subgroups
EES
(n ¼ 3,350)
PES
(n ¼ 1,639) HR (95% CI) p for Interaction*
Age 65 yrs, n ¼ 2,107 8.6 11.4 0.75 (0.57–0.99) 0.59
Age <65 yrs, n ¼ 2,618 9.2 13.3 0.68 (0.54–0.86)
Male, n ¼ 3,235 9.0 11.4 0.76 (0.61–0.96) 0.27
Female, n ¼ 1,490 9.2 14.6 0.62 (0.46–0.84)
Hypertension,y n ¼ 3,602 9.6 12.8 0.74 (0.60–0.91) 0.37
No hypertension, n ¼ 1,117 6.8 11.3 0.60 (0.41–0.90)
Hypercholesterolemia,y n ¼ 3,509 8.9 11.7 0.76 (0.61–0.94) 0.41
No hypercholesterolemia, n ¼ 1,142 9.3 13.9 0.64 (0.45–0.91)
Diabetes, n ¼ 1,432 11.7 12.4 0.96 (0.70–1.32) 0.02
No diabetes, n ¼ 3,286 7.7 12.5 0.60 (0.48–0.75)
Diabetes, insulin-treated, n ¼ 386 15.6 12.4 1.32 (0.75–2.32) 0.02
No diabetes or NITDM, n ¼ 4,332 8.4 12.5 0.66 (0.54–0.80)
NITDM, n ¼ 1,046 10.4 12.3 0.84 (0.58–1.23) 0.30
No diabetes or ITDM, n ¼ 3,678 8.5 12.5 0.67 (0.55–0.82)
Stable angina, n ¼ 2,674 8.7 12.8 0.66 (0.52–0.84) 0.36
No stable angina, n ¼ 1,970 9.4 12.1 0.78 (0.59–1.03)
BMI 30kg/m2, n ¼ 2,160 9.7 12.3 0.79 (0.61–1.02) 0.38
BMI <30kg/m2, n ¼ 2,272 8.5 12.5 0.67 (0.51–0.87)
Single lesion treated, n ¼ 3,658 7.8 10.8 0.72 (0.58–0.90) 0.74
Multiple lesions treated, n ¼ 1,067 12.7 17.9 0.68 (0.49–0.93)
RVD > median 2.76 mm, n ¼ 1,799 6.5 9.1 0.72 (0.51–1.02) 0.95
RVD  median 2.76 mm, n ¼ 1,837 9.1 12.7 0.71 (0.53–0.95)
Length > median 13.3 mm, n ¼ 1,778 8.6 12.8 0.66 (0.49–0.89) 0.44
Length  median 13.3 mm, n ¼ 1,849 7.2 9.2 0.79 (0.57–1.09)
Bailout stent required, n ¼ 400 12.5 22.2 0.53 (0.32–0.87) 0.22
No bailout stent required, n ¼ 4,324 8.6 11.6 0.73 (0.60–0.89)
LAD treated, n ¼ 1,616 7.7 13.3 0.57 (0.42–0.77) 0.03
Non-LAD treated, n ¼ 2,041 7.9 8.8 0.92 (0.67–1.26)
Values are %. Rates are Kaplan-Meier estimates. *The treatment  subgroup interaction p value is from Wald chi-square statistics. The model for Cox
regression analysis includes treatment, subgroup, and treatment  subgroup. yRequiring medication. Single lesion treated data are used for RVD and
lesion length subgroup analyses.
BMI ¼ body mass index; ITDM ¼ insulin-treated diabetes mellitus; NITDM ¼ non-insulin-treated diabetes mellitus; RVD ¼ reference vessel
diameter; other abbreviations as in Tables 1 and 2.
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921stents that may minimize the clinical beneﬁt of the drug-
eluting stent (18). The observed combination of improved
efﬁcacy (reduced rates of TLR) and safety (reduced stent
thrombosis) with EES versus PESmaximizes the potential for
net clinical beneﬁt. In addition, the longer duration of follow-
up in the present study compared with that of prior studies was
required to demonstrate the improvement in freedom from
all-cause and cardiac death with EES compared with PES.
This mortality reduction may be due to the lower rate of very
late (between 1 and 3 years of follow-up) stent thrombosis and
MI with EES compared with PES.
The relative beneﬁts of EES compared with PES were
consistent across the multiple subgroups examined, with the
possible exception of patients with diabetes mellitus and
non-LAD PCI, in whom signiﬁcant differences between
EES and PES were not found. The mechanisms of reste-
nosis and progressive atherosclerosis may indeed differ
between diabetic and nondiabetic patients (19), and therestenosis implications in the LAD territory may be more
clinically overt than in other vessel distributions. However,
the interaction tests for these 2 subgroups were both
borderline (p ¼ 0.02 and 0.03, respectively) and were not
corrected for multiple comparisons. Further studies are
warranted to determine whether there are indeed differences
between EES and PES according to these subgroups.
The present study demonstrating reduced rates of stent
thrombosis with EES compared with PES are concordant
with other direct and indirect (network) meta-analyses that
examined other types of comparator stents (9–11). Potential
reasons for the lower rates of stent thrombosis withEES versus
PES may include: 1) thinner stent struts; 2) the fact that
everolimus is completely eluted within 90 days, whereas
paclitaxel is retained locally in the polymer for a prolonged
period of time; 3) the different modes of action of the 2 drugs,
with potentially more cytotoxicity with paclitaxel; 4) the
presence of a thromboresistant ﬂuoropolymer (8); and 5)
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922greater conformability with a lower risk of strut fracture with
the cobalt chromiumEES platform compared with the thicker
stainless steel device. The Taxus Liberté (Boston Scientiﬁc,
Natick,Massachusetts), a thinner strut stainless steel PES, has
been previously tested with 1- to 2-year safety results similar to
those found in the SPIRIT trials with Taxus Express (6,7).
Thus, reducing the metallic stent strut thickness alone was not
sufﬁcient to reduce stent thrombosis.
Study limitations. Despite the large size of the pooled
population, differences in very low-frequency adverse events
may have escaped detection. Similarly, subgroup testing is
inherently underpowered and should be considered
hypothesis-generating. Routine angiographic follow-up was
performed in a subset of patients in the SPIRIT II and III
trials, which may have increased the absolute difference in
ischemia-driven TLR between the 2 stents, but would not
have affected their relative efﬁcacy, nor measures of stent
safety (1–4). Finally, the SPIRIT trials excluded numerous
high-risk categories of patients and lesions, including those
with thrombus and ST-segment elevation MI, true bifur-
cation lesions, chronic total occlusions and saphenous vein
grafts, and heavily calciﬁed and tortuous lesions. However,
additional data from an all-comers randomized trial suggest
that EES may also be safer and more effective than PES in
more complex subsets of patients and lesions (6).
Conclusions
The results from this large-scale meta-analysis from 3
similarly performed, prospective randomized trials with
3-year follow-up after the index coronary implantation of
EES compared with PES demonstrate substantially reduced
rates of all-cause mortality, MI, ischemia-driven TLR, stent
thrombosis, TLF, target vessel failure, and MACE with
EES. These data emphasize that stent selection decisions
can markedly affect the long-term outcomes of patients with
coronary artery disease undergoing PCI. Finally, the ﬁnd-
ings of the present analysis challenge the generalizability (to
contemporary clinical decision making) of the results from
previously completed large clinical trials that had used less
safe and/or effective drug-eluting stent devices that are no
longer in widespread use.
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